Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an exploratory meta-analysis.

Autor: Nottegar A; Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy., Veronese N; Department of Medicine, DIMED, University of Padua, Padua, Italy., Senthil M; Department of Surgery, Loma Linda University, Loma Linda, CA, USA., Roumen RM; Department of Medical Oncology, School for Oncology and Developmental Biology (GROW), Maastricht University Medical Center, Maastricht, The Netherlands., Stubbs B; Health Service and Population Research Department, King's College London, De Crespigny Park, London, UK., Choi AH; Department of Surgery, Loma Linda University, Loma Linda, CA, USA., Verheuvel NC; Department of Surgery, Máxima Medical Center, Veldhoven, The Netherlands., Solmi M; Department of Neuroscience, University of Padua, Padua, Italy., Pea A; Department of Surgery, University and Hospital Trust of Verona, Verona, Italy., Capelli P; Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy., Fassan M; Department of Medicine, DIMED, University of Padua, Padua, Italy., Sergi G; Department of Medicine, DIMED, University of Padua, Padua, Italy., Manzato E; Department of Medicine, DIMED, University of Padua, Padua, Italy., Maruzzo M; Medical Oncology Unit, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy., Bagante F; Department of Surgery, University and Hospital Trust of Verona, Verona, Italy., Koç M; Necmettin Erbakan University, Meram Medical School Department of Radiation Oncology, Konya, Turkey., Eryilmaz MA; Health Science University, Konya Training and Educational Hospital, Department of General Surgery, Konya, Turkey., Bria E; Medical Oncology, University and Hospital Trust of Verona, Verona, Italy., Carbognin L; Medical Oncology, University and Hospital Trust of Verona, Verona, Italy., Bonetti F; Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy., Barbareschi M; Department of Pathology, Santa Chiara Hospital, Trento, Italy., Luchini C; Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy; Department of Pathology, Santa Chiara Hospital, Trento, Italy; ARC-NET Research Center, University and Hospital Trust of Verona, Verona, Italy. Electronic address: claudio.luchini@katamail.com.
Jazyk: angličtina
Zdroj: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2016 Jul; Vol. 42 (7), pp. 919-25. Date of Electronic Publication: 2016 Mar 10.
DOI: 10.1016/j.ejso.2016.02.259
Abstrakt: Invasive breast cancer is the most common malignancy in women. Its most common site of metastasis is represented by the lymph nodes of axilla, and the sentinel lymph node (SLN) is the first station of nodal metastasis. Axillary SLN biopsy accurately predicts axillary lymph node status and has been accepted as standard of care for nodal staging in breast cancer. To date, the morphologic aspects of SLN metastasis have not been considered by the oncologic staging system. Extranodal extension (ENE) of nodal metastasis, defined as extension of neoplastic cells through the nodal capsule into the peri-nodal adipose tissue, has recently emerged as an important prognostic factor in several types of malignancies. It has also been considered as a possible predictor of non-sentinel node tumor burden in SLN-positive breast cancer patients. We sought out to clarify the prognostic role of ENE in SLN-positive breast cancer patients in terms of overall and disease-free survival by conducting a systematic review and meta-analysis. Among 172 screened articles, 5 were eligible for the meta-analysis; they globally include 624 patients (163 ENE+ and 461 ENE-) with a median follow-up of 58 months. ENE was associated with a higher risk of both mortality (RR = 2.51; 95% CI: 1.66-3.79, p < 0.0001, I(2) = 0%) and recurrence of disease (RR = 2.07, 95% CI: 1.38-3.10, p < 0.0001, I(2) = 0%). These findings recommend the consideration of ENE from the gross sampling to the histopathological evaluation, in perspectives to be validated and included in the oncologic staging.
(Copyright © 2016 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: